Cure8 research brief
ANCA testing is used beyond classic vasculitis diagnoses and IIF can still be clinically valuable in specific situations. For people with IBD or other autoimmune conditions, understanding which ANCA tests are useful may affect diagnostic workups and specialist referrals.
Clinicians, laboratory specialists, researchers, and patients with autoimmune disease (including IBD) undergoing ANCA testing.
This review summarizes the role of indirect immunofluorescence (IIF) for detecting anti-neutrophil cytoplasmic antibodies (ANCA). The authors searched PubMed through June 2026 and discuss where IIF remains useful despite high-quality immunoassays for PR3-ANCA and MPO-ANCA largely replacing IIF in routine screening for ANCA-associated vasculitis.
The review highlights clinical scenarios where IIF can add value: suspected drug-induced vasculitis, cocaine-associated disease, infective endocarditis, and select non-vasculitis conditions such as connective tissue diseases, autoimmune liver disease, and inflammatory bowel disease.
It frames IIF as a complementary tool rather than the primary screening test in most current practice. The paper is a literature review (Expert Review of Clinical Immunology). It synthesizes published studies and case series but does not present new trial data or patient-level outcomes.
Narrative review (Expert Review of Clinical Immunology) synthesizing studies and case series through June 2026; does not present new trial data.
Review the original publication for the complete reporting, methods, and context.
This Cure8 brief is based on source text from the linked article. Cure8 is informational only and is not a substitute for professional medical advice, diagnosis, or treatment.
Noninvasive fecal tests can help detect intestinal inflammation without repeated endoscopy and support treat-to-target care. Better biomarkers could mean earlier treatment changes and less invasive monitoring for people...
A blood biomarker (OSM) that tracks microscopic inflammation could help detect residual disease activity that fecal calprotectin and routine clinical scores miss. That matters because histological inflammation predicts...
Non-invasive biomarkers that reflect mucosal inflammation and systemic disease activity could help reduce reliance on frequent endoscopy and guide monitoring for people with Crohn’s disease or ulcerative colitis.
